This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group. The board (the “Board”) of directors (“Directors”, and each a “Director”) of the Company is pleased to announce that the Group has submitted the application for Phase Ill clinical trial of IMM0306 to the Center for Drug Evaluation of National Medical Products Administration of the People’s Republic of China (the “NMPA”). 

ABOUT IMM0306 

IMM0306, independently developed by the Group, is a bispecific molecule targeting both cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20) and is the first CD47 and CD20 dual-targeting bispecific to enter into clinical stage globally. IMM0306 blocks the “don’t eat me” signal by inhibiting the CD47-SIRPα interaction, enhances Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and NK cells, and preferentially binds CD20 over CD47 to effectively eliminate malignant B cells while minimizing toxicity, leading to improved therapeutic outcomes. 

As of the date of this announcement, the Group owns the global intellectual property rights and commercial rights of IMM0306.